Similar Search Results

Preferences for health insurance in Germany and the Netherlands : a tale of two countries

Leukert-Becker, Karolin; Zweifel, Peter - In: Health economics review 4 (2014) 22, pp. 1-11

Background: This contribution seeks to measure preferences for health insurance in Germany and the Netherlands, using …

Persistent link: https://www.econbiz.de/10010526906

Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

Clouth, Johannes; Liepa, Astra M.; Moeser, Guido; … - In: Health economics review 8 (2018) 18, pp. 1-10

-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria. Methods …-sorafenib. Results: Between 1032 and 1484 patients with HCC in Germany (893–1390 publicly insured patients) were estimated as likely to … publicly insured HCC patients annually eligible for second-line therapy in Germany was < 1400 and mean total costs accrued in …

Persistent link: https://www.econbiz.de/10011896545

Kernpunkte einer Krankenversicherungsreform

Külp, Bernhard - In: Wirtschaftswissenschaftliches Studium : WiSt ; … 36 (2007) 4, pp. 192-197

Persistent link: https://www.econbiz.de/10003443953

Promoting vaccinations - an analysis of measures taken by German statutory health insurers

Damm, Kathrin; Schubert, Jana M.; Schulenburg, … - In: Health economics review 1 (2011) 16, pp. 1-6

prophylactic vaccinations this rate is not reached in Germany. In order to counteract this trend the importance of prophylactic …

Persistent link: https://www.econbiz.de/10009503925

Impact of radiofrequency ablation for patients with varicose veins on the budget of the German statutory health insurance system

Kuhlmann, Alexander; Prenzler, Anne; Hacker, Jan; … - In: Health economics review 3 (2013) 9, pp. 1-17

in Germany. However, radiofrequency ablation, e.g. ClosureFast, becomes more and more popular in other countries due to … calculating the budget impact of a general reimbursement of ClosureFast in Germany. Methods: To assess the budget impact of … of about 19.1Mio. € over a time horizon of five years in Germany. However, the results scatter in the sensitivity …

Persistent link: https://www.econbiz.de/10009756028

Der Fluch des Zweitbesten : der Risikostrukturausgleich in der gesetzlichen Krankenversicherung

Felder, Stefan - In: Wirtschaftswissenschaftliches Studium : WiSt ; … 30 (2001) 11, pp. 583-587

Persistent link: https://www.econbiz.de/10001617841

Der Risikostrukturausgleich zwischen den Gesetzlichen Krankenkassen : notwendiger Garant der Solidarität oder Bestandsschutz für leistungsschwache Krankenkassen?

Oberender, Peter; Fleischmann, Jochen - In: Wirtschaftswissenschaftliches Studium : WiSt ; … 30 (2001) 11, pp. 599-606

Persistent link: https://www.econbiz.de/10001617847

Gesundheitsfonds : alles wieder auf den Anfang zurück?

Oberender, Peter - In: Wirtschaftswissenschaftliches Studium : WiSt ; … 37 (2008) 7, pp. 349, 355

Persistent link: https://www.econbiz.de/10003737212

Medical Savings Accounts : Darstellung, Würdigung und Übertragbarkeit auf die gesetzliche Krankenversicherung

Daumann, Frank; Bornemann, Stefan - In: Wirtschaftswissenschaftliches Studium : WiSt ; … 35 (2006) 10, pp. 542-547

Persistent link: https://www.econbiz.de/10003384173

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25

assessment in Germany since its introduction in 2011 up to September 2016. Methods: It was differentiated between additive (new …

Persistent link: https://www.econbiz.de/10012291135